(Q43515124)

24 November 2017

title

Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies (English)

1 reference

24 November 2017

Jane Kendrew

1

1 reference

24 November 2017

Rajesh Odedra

2

1 reference

24 November 2017

Armelle Logié

3

1 reference

24 November 2017

Paula J Taylor

4

1 reference

24 November 2017

Sharon Pearsall

5

1 reference

24 November 2017

Donald J Ogilvie

6

1 reference

24 November 2017

Stephen R Wedge

7

1 reference

24 November 2017

Juliane M Jürgensmeier

8

1 reference

24 November 2017

publication date

26 January 2013

1 reference

Cancer Chemotherapy and Pharmacology

24 November 2017

published in

1 reference

24 November 2017

volume

71

1 reference

24 November 2017

issue

4

1 reference

24 November 2017

page(s)

1021-1032

1 reference

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

A physiologic imaging pilot study of breast cancer treated with AZD2171.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

VEGF-targeted therapy: mechanisms of anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2097-X

10.1007/S00280-013-2097-X

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

24 November 2017

1011172222

0 references

1 reference